In this study, we used more than 47,000 patients from the Memorial Sloan Kettering-Metastatic Events and Tropisms (MSK-MetTropism) [13], the Memorial Sloan Kettering-Integrated Mutational Profiling of Actionable Cancer Targets (MSK-IMPACT) [14], the China pan-cancer (OrigiMed2020) [15]and the Cancer Genome Atlas (TCGA) cohorts [16] to explore the characteristics of CDKN2A ALT, MUT or DEL and their associations with clinical outcomes and response to ICIs among pan-cancer patients treated or not treated with immunotherapy. This evidence concerns the gene GPT and cancer.